Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project
Lange, B.; Jaeger, V. K.; Harries, M.; Ruecker, V.; Streeck, H.; Blaschke, S.; Petersmann, A.; Toepfner, N.; Nauck, M.; Hassenstein, M. J.; Dreier, M.; von Holt, I.; Budde, A.; Bartz, A.; Ortmann, J.; Kurosinski, M.-A.; Berner, R.; Borsche, M.; Brandhorst, G.; Brinkmann, M.; Budde, K.; Deckena, M.; Engels, G.; Fenzlaff, M.; Haertel, C.; Hovardovska, O.; Katalinic, A.; Kehl, K.; Kohls, M.; Krueger, S.; Lieb, W.; Meyer-Schlinkmann, K. M.; Pischon, T.; Rosenkranz, D.; Ruebsamen, N.; Rupp, J.; Schaefer, C.; Schattschneider, M.; Schlegtendal, A.; Schlinkert, S.; Schmidbauer, L.; Schulze-Wundling, K
Show abstract
Despite the need to generate valid and reliable estimates of protection against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real-time. In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n=33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses ("confirmed exposures"). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest. Most participants were seropositive against the spike antigen; 37% of the participants [≥]79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4%-28% of participants having less than three confirmed exposures. Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of a nationwide serosurvey in the Netherlands 92%
- COVID-19 vaccination and short-term mortality risk: a nationwide self-controlled case series study in The Netherlands 91%
- Circulating insulin-like growth factor-I and risk of 25 common conditions: outcome-wide analyses in the UK Biobank Study 90%
Similar papers in this journal
- A unified framework for estimating country-specific cumulative incidence for 18 diseases stratified by polygenic risk 95%
- Typically asymptomatic but with robust antibody formation: Children’s unique humoral immune response to SARS-CoV-2 94%
- Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population 94%
Similar papers in this journal
- Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden 94%
- SARS-CoV-2 infection in households with and without young children: Nationwide cohort study 94%
- Unexposed populations and potential COVID-19 burden in European countries 93%
Similar papers in this journal
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021 93%
- Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study 92%
- Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) 92%
Similar papers in this journal
- Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohort 92%
- Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID) 92%
- Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.